giulia

MD

[Noemi Reguart @NReguart]

Nice discussion by Dr Lyudmila Bazhenova: EGFR exon20ins: how to choose first-line?
PAPILLON ➜ ami + chemo
WU-KONG28 ➜ sunvozertinib
REZILIENT3 ➜ zipalertinib + chemo
Efficacy, safety, CNS, treatment burden, patient preference & what comes next?
#WCLC26 #EGFR #NSCLC #LCSM

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

🇨🇳 phase 3 ARTEMIS-008 trial comparing Ris-Rez versus topotecan for the treatment of relapsed SCLC.
Impressive 18.5 months overall survival with HR 0.46, but higher ILD incidence 11.7% and Gr 3-4 AEs. Solid results to be confirmed in ongoing global studies. #LCSM #WCLC26 @IASLC

[gilberto lopes @GlopesMd]

Potentially practice-changing #WCLC26 Presidential Symposium result:

SWOG S1827/MAVERICK

MRI surveillance alone vs PCI + MRI surveillance in SCLC.

Primary endpoint favored MRI alone:
CFFS HR 0.60
6 mo: 38% vs 17%
12 mo: 17% vs 6%

[Yakup Ergün @dr_yakupergun]

Highlighted Studies at #WCLC26

1️⃣ HARMONi-2
In treatment-naïve, advanced NSCLC with PD-L1 ≥1%, ivonescimab improved PFS (11.1 vs 5.8 months; HR 0.51) and OS (30.8 vs 22.6 months; HR 0.73) compared with pembrolizumab.
This is a genuinely positive trial, but it does not tell the same story for all PD-L1-positive patients. The OS benefit was clear in the ≥50% subgroup, whereas the HR was 0.85 with a confidence interval crossing 1 in the 1–49% subgroup. Moreover, pembrolizumab monotherapy is not the real comparator for most patients in this group; chemo-IO is.

2️⃣ SWOG S1827/MAVERICK
In patients with SCLC who had completed initial treatment and had no brain metastases, MRI surveillance was compared with MRI plus PCI. MRI alone reduced the risk of cognitive failure or death (HR 0.60); grade ≥3 toxicity was 0.8% vs 7.9%. Interim OS and brain metastasis-free survival were not different.
The study does not show that MRI prevents brain metastases more effectively. It shows that adding PCI has so far caused cognitive and serious toxicity without demonstrating a survival benefit. If regular MRI and prompt salvage treatment can be provided, routine PCI is now difficult to justify. Still, it is too early to say that PCI is completely dead before the final OS analysis.

3️⃣ TAISHAN-302
In relapsed SCLC, the B7-H3 ADC Tam-Peli improved OS from 9.4 to 13.3 months versus topotecan (HR 0.46); PFS was 7.4 vs 2.8 months and ORR was 59% vs 10%. Grade ≥3 treatment-related toxicity was also lower.

ARTEMIS-008
In relapsed SCLC, another B7-H3 ADC, Ris-Rez, also outperformed topotecan: OS was 18.5 vs 10.3 months (HR 0.46), PFS was 7.2 vs 3.0 months, and ORR was 58% vs 13%.
Together with TAISHAN-302, this result strongly confirms that B7-H3 is a genuine target in SCLC. However, the median OS figures from the two trials cannot be used to conclude that Ris-Rez is better. The choice between the two ADCs may be determined more by ILD, hematologic toxicity, and ease of administration than by efficacy figures. The efficacy of either agent after tarlatamab maintenance also remains unknown.

5️⃣ EVOKE-03/KEYNOTE-D46
In metastatic NSCLC with PD-L1 ≥50%, sacituzumab govitecan plus pembrolizumab increased ORR compared with pembrolizumab (%56 vs 44%) and numerically prolonged PFS, but the prespecified statistical threshold was not met. OS was 21.5 vs 22.8 months, duration of response was almost identical, and grade ≥3 toxicity was 56% vs 17%.
Adding the ADC shrank tumors in more patients but did not change the natural course of the disease. Considering the similar duration of response, lack of OS benefit, and substantial toxicity, this combination has no place in clinical practice.

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

Just received this.

The golden era in SCLC!

The DeLLphi-305 (Phase 3 Study in First-Line ES-SCLC Following Platinum, Etoposide and Durvalumab) OS Interim Analysis has been conducted. The analysis has demonstrated a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi® (durvalumab) compared to durvalumab alone.
https://t.co/DXLmkDT5Yz

[AbdAllah Othman @CardioBeat_]

📈 ECG Cheat Sheet 🎯
https://t.co/WXIjnxTmXo
Drop a ❤️ 🤓 if you find this helpful! Feel free to share!
#ECG #EKG #Cardiology #MedStudent #NursingSchool #MedEd #Clinical #CheatSheet #Arrhythmia

[Lucia Del Mastro @delmastro_lucia]

👉 Vi invito a esprimere il Vostro voto al seguente link: 
https://
https://t.co/vnDjt1R1Ch
fit

Un’AIOM più vicina ai soci, alla ricerca, ai giovani e alla prevenzione. Il mio programma si fonda su una parola chiave: INSIEME

#AIOM 
#INSIEME

[Istituto Superiore di Sanità @istsupsan]

🌍 Oggi #17ottobre ricorre la Giornata Mondiale per l'eradicazione della #Povertà e quest’anno la @WHO ha scelto come focus il rispetto ed il supporto alle #famiglie indigenti, spesso spinte ai margini della società.
🔎Visita la pagina delle Nazioni Unite: https://t.co/1wrur69ukf

[Matteo Lambertini, MD PhD @matteolambe]

La prima pubblicazione della nostra super @delmastro_lucia a #ESMO25 con il dato di sopravvivenza globale dallo studio #momarchE 💪 🙌👏

@AIOMtweet @OncoAlert @Annals_Oncology @OncoAlert @UniGenova

[Andrea Boutros @boutrosand]

#INSIEME a @delmastro_lucia 💪🏽

[Zara @Zarabaq]

Kiss from the middle of our camp to everyone who has supported us.

[Lucia Del Mastro @delmastro_lucia]

Oggi al Festival della Salute di Padova, insieme a Elena Cattaneo, Alberto Mantovani e Rosario Rizzuto, per discutere di come difendere la scienza e la medicina da disinformazione e negazionismo.

L’Europa può e deve guidare questa sfida.

@repubblica

[Lucia Del Mastro @delmastro_lucia]

Garantire accesso equo e basato sull’evidenza ai trattamenti oncologici è una priorità.

@AIOMtweet deve continuare a essere interlocutore di riferimento nei tavoli tecnici di @Aifa_ufficiale, per decisioni 
trasparenti e a tutela dei pazienti.

[Jordi Remon @JordiRemon]

Pts with NSCLC 🫁 and asymptomatic brain mets 🧠, is a poor Px popul.The intensification of 1st line with addition antiCA4 drug (Nivo+Ipi+2 cycles CT like CheckMate9LA) did not reached primary endpoint in NIVIPI-Brain trial.CT+IO remains SoC and new agents are awaited #WCLC2025

[Alessandro Leonetti @Ale_leonetti]

Honored to present the results of the LiBRA study at #WCLC25, focusing on patients with #BRAF V600E–mutant #NSCLC treated with dabrafenib + trametinib.

An important step towards molecular monitoring in this rare NSCLC subset.

#lungcancer #liquidbiopsy #GOIRC

[Benjamin Besse @BenjaminBesseMD]

EGFR update
7 potential options:
•3rd gen TKI: osimertinib, lazertinib, aumolertinib
•Amivantamab
•Pemetrexed
•Carboplatin
•Ivonescimab
•Dato-DXd
OS data favor combos upfront—but real-world ≠ trial. In RWD, ~40% of newly diagnosed pts wouldn’t qualify for FLAURA2 #WCLC25

[Jordi Remon @JordiRemon]

PECATI Trial,lenvatinib plus pembrolizumab (20/200) a potential ttx for pts w metastatic pretreated B3-Thymoma or TC
-mPFS 14.9mo
-ORR: 23.3%
-1-y OS: 85.2%
-G3 irAEs: 14%
-Keep Dose intensity lenva first 8 weeks ⬆️ PFS
Thanks to all authors!!
DOI: 10.1016/S1470-2045(25)00300-6

[Matteo Lambertini, MD PhD @matteolambe]

Forza @delmastro_lucia…tutti #INSIEME…per @AIOMtweet !!!!

@OncoAlert @UniGenova @Lucarecco @Poggio_Fra @M_Tagliamento @DSoldatoMD @CarloGenova5 @MRazeti @ChiaraMolinelli @boutrosand

[Lucia Del Mastro @delmastro_lucia]

Onorata di intervenire a #ESCCardioOnco2025

La collaborazione tra diversi specialisti è un esempio concreto di quanto la multidisciplinarietà sia cruciale nella cura del cancro @escardio @AIOMtweet

#cardiooncology #collaborazione #oncologia #cardiologia #INSIEME

[Ospedale San Martino Genova @SanMartino_Ge]

Maxi-studio guidato da @SanMartino_Ge con sostegno di @AIRC_it: mastectomia bilaterale e ovariectomia riducono fino al 42% il rischio di recidiva e mortalità anche in donne #BRCA mutate già colpite da #tumorealseno in giovane età.

👉https://t.co/KmTYT4e5h7

@TheLancetOncology